<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27557121</article-id><article-id pub-id-type="pmc">4996463</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0161484</article-id><article-id pub-id-type="publisher-id">PONE-D-16-23668</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Radiology and Imaging</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Radiation Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Oncology</subject><subj-group><subject>Radiation Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Clinical Oncology</subject><subj-group><subject>Radiation Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Prospective Studies</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Blastomas</subject><subj-group><subject>Glioblastoma Multiforme</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Neurological Tumors</subject><subj-group><subject>Glioblastoma Multiforme</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurological Tumors</subject><subj-group><subject>Glioblastoma Multiforme</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Image Analysis</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients</article-title><alt-title alt-title-type="running-head">A Geometrical Measure Predicts Response to Bevacizumab in Glioblastoma</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6104-3894</contrib-id><name><surname>Molina</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>P&#x000e9;rez-Beteta</surname><given-names>Juli&#x000e1;n</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>Alicia</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sep&#x000fa;lveda</surname><given-names>Juan M.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peralta</surname><given-names>Sergi</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gil-Gil</surname><given-names>Miguel J.</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Reynes</surname><given-names>Gaspar</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Herrero</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>De Las Pe&#x000f1;as</surname><given-names>Ram&#x000f3;n</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Luque</surname><given-names>Raquel</given-names></name><xref ref-type="aff" rid="aff008"><sup>8</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Capellades</surname><given-names>Jaume</given-names></name><xref ref-type="aff" rid="aff009"><sup>9</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bala&#x000f1;a</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="aff010"><sup>10</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>V&#x000ed;ctor M.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Laboratory of Mathematical Oncology (M&#x000f4;LAB), Instituto de Matem&#x000e1;tica Aplicada a la Ciencia y la Ingenier&#x000ed;a, Edificio Polit&#x000e9;cnico, Avda. Camilo Jos&#x000e9; Cela 3, Universidad de Castilla-La Mancha, 13071 Ciudad Real, Spain</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Medical Oncology Service, Hospital Universitario, 12 de Octubre, Madrid, Spain</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Medical Oncology Service, Institut Catal&#x000e1; d&#x02019;Oncologia IDIBELL, Hospitalet de Llobregat, Barcelona, Spain</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain</addr-line></aff><aff id="aff007"><label>7</label><addr-line>Medical Oncology Service, Hospital Provincial de Castell&#x000f3;n, Castell&#x000f3;n, Spain</addr-line></aff><aff id="aff008"><label>8</label><addr-line>Medical Oncology Service, Hospital Universitario Virgen de las Nieves, Granada, Spain</addr-line></aff><aff id="aff009"><label>9</label><addr-line>Neuroradiology Section. Radiology Service. Hospital del Mar, Barcelona, Spain</addr-line></aff><aff id="aff010"><label>10</label><addr-line>Medical Oncology Service, Institut Catal&#x000e0; d&#x02019;Oncologia, IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Sherman</surname><given-names>Jonathan H</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>George Washington University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> DM JPB AMG CB VMPG.</p></list-item><list-item><p><bold>Data curation:</bold> JMS SP MJGG GR AH RDLP RL JC CB.</p></list-item><list-item><p><bold>Formal analysis:</bold> DM JPB AMG VMPG.</p></list-item><list-item><p><bold>Funding acquisition:</bold> CB VMPG.</p></list-item><list-item><p><bold>Investigation:</bold> DM JPB AMG VMPG.</p></list-item><list-item><p><bold>Methodology:</bold> DM JPB AMG CB VMPG.</p></list-item><list-item><p><bold>Project administration:</bold> CB VMPG.</p></list-item><list-item><p><bold>Resources:</bold> JMS SP MJGG GR AH RDLP RL JC CB.</p></list-item><list-item><p><bold>Software:</bold> DM JPB AMG VMPG.</p></list-item><list-item><p><bold>Supervision:</bold> CB VMPG.</p></list-item><list-item><p><bold>Validation:</bold> DM JPB AMG VMPG.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> DM JPB AMG CB VMPG.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> DM JPB AMG CB VMPG.</p></list-item></list></p></fn><fn fn-type="other" id="econtrib001"><p>&#x02021; These authors also contributed equally to this work.</p></fn><corresp id="cor001">* E-mail: <email>david.molina@uclm.es</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>8</issue><elocation-id>e0161484</elocation-id><history><date date-type="received"><day>13</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>6</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Molina et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Molina et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0161484.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start of the therapy.</p></sec><sec id="sec002"><title>Methods</title><p>40 patients from the randomized GENOM009 study complied the inclusion criteria (quality of images, clinical data available). Of those, 23 patients received first line temozolomide (TMZ) for eight weeks and then concomitant radiotherapy and TMZ. 17 patients received BVZ+TMZ for seven weeks and then added radiotherapy to the treatment. Clinical variables were collected, tumors segmented and several geometrical measures computed including: Contrast enhancing (CE), necrotic, and total volumes; equivalent spherical CE width; several geometric measures of the CE &#x02018;rim&#x02019; geometry and a set of image texture measures. The significance of the results was studied using Kaplan-Meier and Cox proportional hazards analysis. Correlations were assessed using Spearman correlation coefficients.</p></sec><sec id="sec003"><title>Results</title><p>Kaplan-Meier and Cox proportional hazards analysis showed that total, CE and inner volume (p = 0.019, HR = 4.258) and geometric heterogeneity of the CE areas (p = 0.011, HR = 3.931) were significant parameters identifying response to BVZ. The group of patients with either regular CE areas (small geometric heterogeneity, median difference survival 15.88 months, p = 0.011) or those with small necrotic volume (median survival difference 14.50 months, p = 0.047) benefited substantially from BVZ.</p></sec><sec id="sec004"><title>Conclusion</title><p>Imaging biomarkers related to the irregularity of contrast enhancing areas and the necrotic volume were able to discriminate GBM patients with a substantial survival benefit from BVZ. A prospective study is needed to validate our results.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Ministerio de Econom&#x000ed;a y Competitividad (ES)</institution></funding-source><award-id>MTM2015-71200-R</award-id><principal-award-recipient><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>V&#x000ed;ctor M.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Consejer&#x000ed;a de Educaci&#x000f3;n, Cultura y Deporte (JCCLM)</institution></funding-source><award-id>PEII-2014-031-P</award-id><principal-award-recipient><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>V&#x000ed;ctor M.</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000913</institution-id><institution>James S. McDonnell Foundation</institution></institution-wrap></funding-source><award-id>220020420</award-id><principal-award-recipient><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>V&#x000ed;ctor M.</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000913</institution-id><institution>James S. McDonnell Foundation</institution></institution-wrap></funding-source><award-id>220020450</award-id><principal-award-recipient><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>V&#x000ed;ctor M.</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>FISS-ICIII: project EC08/00071</award-id><principal-award-recipient><name><surname>Bala&#x000f1;a</surname><given-names>Carmen</given-names></name></principal-award-recipient></award-group><funding-statement>This work has been supported by Ministerio de Econom&#x000ed;a y Competitividad/FEDER, Spain [grant number MTM2015-71200-R], Consejer&#x000ed;a de Educaci&#x000f3;n Cultura y Deporte from Junta de Comunidades de Castilla-La Mancha, Spain [grant number PEII-2014-031-P] and James S. Mc. Donnell Foundation 21st Century Science Initiative in Mathematical and Complex Systems Approaches for Brain Cancer [Special Initiative Collaborative &#x02013; Planning Grant 220020420 and Collaborative award 220020450]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="6"/><page-count count="16"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Glioblastoma (GBM) is the most frequent type of malignant primary brain tumor and the most lethal type. The standard of care includes maximal safe surgery plus concurrent treatment with temozolomide (TMZ) and radiotherapy followed by maintenance TMZ, what leads to a median survival of 14.6 months [<xref rid="pone.0161484.ref001" ref-type="bibr">1</xref>].</p><p>Since GBM is one of the most vascularized human tumors it was thought that antiangiogenic treatment approaches might offer an alternative or complementary treatment strategy. Specifically, bevacizumab (BVZ), a humanized monoclonal antibody, has been in the spotlight of antiangiogenic approaches for several years [<xref rid="pone.0161484.ref002" ref-type="bibr">2</xref>].</p><p>Three randomized comparative phase III trials, two for newly diagnosed patients (AVAGLIO {ClinicalTrials.gov number NCT00943826} and RTOG08025 {ClinicalTrials.gov number NCT00884741}) [<xref rid="pone.0161484.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0161484.ref004" ref-type="bibr">4</xref>] and one for recurrent GBMs (EORTC 26101{ClinicalTrials.gov number NCT01290939}) [<xref rid="pone.0161484.ref005" ref-type="bibr">5</xref>], reported negative results for the primary endpoint of overall survival (OS) but significant positive results for the BVZ arm in terms of progression-free survival (PFS) and overall response rate (ORR).</p><p>Nevertheless, there is a widespread, albeit statistically unsupported, perception that some patients do benefit from BVZ and that a response to BVZ predicts longer survival [<xref rid="pone.0161484.ref006" ref-type="bibr">6</xref>]. In fact, a population-based report highlighted an increase in survival among US GBM patients only attributable to the generalized use of BVZ in the recurrent setting following FDA approval [<xref rid="pone.0161484.ref007" ref-type="bibr">7</xref>].</p><p>Unfortunately, there is no reliable way to preselect patients who are most likely to respond to BVZ. Several studies have examined the possibility of selecting patients based on their molecular profile [<xref rid="pone.0161484.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0161484.ref009" ref-type="bibr">9</xref>] or on an early detection of response by image analysis [<xref rid="pone.0161484.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0161484.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0161484.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0161484.ref013" ref-type="bibr">13</xref>].</p><p>Preoperative Magnetic resonance imaging (MRI) is routinely used for diagnosis, treatment planning, response evaluation and follow-up. Typical GBM appearance upon diagnosis on MRI consists of an enhancing ring mass with central non-enhancing core of necrosis observed mainly on contrast enhanced T1-weighted images; this is surrounded by an area of signal hyperintensity on fluid-attenuated inversion recovery FLAIR or T2 images representing edema that is well known to contain infiltrated tumor cells.</p><p>The areas of signal hyperintensity, were the contrast agent is released, indicate abnormal vessel permeability due to either the breakup of the blood-brain-barrier or the presence of inmature tumoral vessels. Typically, those areas have enhanced perfusion and its presence related to angiogenic processes.</p><p>There is an increasing evidence supporting that the geometrical and textural properties of tumors can lead to novel imaging biomarkers of prognosis and response. P&#x000e9;rez-Garc&#x000ed;a et al [<xref rid="pone.0161484.ref014" ref-type="bibr">14</xref>] developed a mathematical model predicting a positive correlation between the tumor rim width as observed in the postcontrast T1-weighted MRIs and tumor&#x02019;s aggressiveness. This was later validated on a set of 117 GBM patients [<xref rid="pone.0161484.ref015" ref-type="bibr">15</xref>]. Other works have studied classical geometrical (volumetric) measures obtained from pretreatment T1 images as prognostic &#x0201c;biomarkers&#x0201d; [<xref rid="pone.0161484.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0161484.ref017" ref-type="bibr">17</xref>]. Also, textural features in brain cancer have been widely studied to investigate their prognostic value [<xref rid="pone.0161484.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0161484.ref019" ref-type="bibr">19</xref>], discriminate tumor phenotypes [<xref rid="pone.0161484.ref020" ref-type="bibr">20</xref>] or automatically detection and classification of low and high grade glioma [<xref rid="pone.0161484.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0161484.ref022" ref-type="bibr">22</xref>].</p><p>The applicability of this kind of analysis to assess response to antiangiogenic treatment has not been put forward before.</p><p>In this paper we characterized the geometry and texture of pretreatment contrast enhancing (CE) areas in T1 weighted MRI images and correlated the resulting measures with survival benefits from BVZ. Our goal was to find novel imaging biomarkers predictive of antiangiogenic treatment efficacy in GBM patients.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and Methods</title><sec id="sec007"><title>Patients</title><p>The GENOM009 trial {ClinicalTrials.gov number NCT01102595} was a multicenter, prospective trial of neo-adjuvant therapy including 93 unresected patients with diagnosed GBM [<xref rid="pone.0161484.ref023" ref-type="bibr">23</xref>]. Patients were randomized 1:1 to either the temozolomide (TMZ) or the BVZ (TMZ+BVZ) arm. In the TMZ arm, neoadjuvant treatment consisted of TMZ for 2 cycles and then concurrent treatment with radiation therapy plus TMZ. In the TMZ+BVZ arm, patients received the same regimens but with the addition of BVZ in the neoadjuvant stage and concurrent stage. In both arms, the concurrent stage was followed by a 28-day break in treatment and then by adjuvant treatment with TMZ for six cycles without BVZ. The primary endpoint was investigator-assessed response after the neoadjuvant stage (week 9) according to the Response Assessment in Neuro-Oncology (RANO) Criteria [<xref rid="pone.0161484.ref024" ref-type="bibr">24</xref>]. Secondary endpoints were PFS, OS, 1-year survival among others. Results of this trial have been recently published showing that the addition of BVZ conferred a higher response rate (22.9% vs 6.7%; P&#x0003c;0.001) and greater clinical benefit (60.4% vs 24.5%; P&#x0003c;0.001). These results were confirmed upon centralized blinded review. PFS (4.8 vs 2.2 months) and OS (10.6 vs 7.7 months) were also longer in patients treated with the combination of TMZ+BVZ, though the difference did not reach statistical significance.</p><p>The inclusion criteria for this work were: availability of all of the relevant clinical variables (age, overall survival, etc.) and availability of high quality (no movement or other artifacts) pretreatment postcontrast T1-weighted MRIs. Multifocal GBMs and tumors without contrast enhancement were excluded from the study. Overall survival was measured from time of surgery to patient&#x02019;s last contact or death.</p><p>High-resolution pre-surgery postcontrast T1-weighted MRIs were available for 53 patients, of which 13 were discarded due to either no contrast enhancement, diffuse data or presence of MRI noise. Therefore, 40 patients complied with inclusion criteria, 17 in the TMZ+BVZ arm and 23 in the TMZ arm. Patients' characteristics are summarized in <xref ref-type="table" rid="pone.0161484.t001">Table 1</xref>.</p><table-wrap id="pone.0161484.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.t001</object-id><label>Table 1</label><caption><title>Summary of patient characteristics, MRI data and volumetric parameters for the 40 patients included in the study.</title></caption><alternatives><graphic id="pone.0161484.t001g" xlink:href="pone.0161484.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" colspan="2" rowspan="1"><bold><italic>Patient characteristics</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Age (median, range)</td><td align="left" rowspan="1" colspan="1">64 (36&#x02013;74)</td></tr><tr><td align="left" rowspan="2" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">21 Male (52.50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">19 Female (47.50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Survival (median, range)</td><td align="left" rowspan="1" colspan="1">10.78 months (2.30&#x02013;52.33)</td></tr><tr><td align="left" rowspan="2" colspan="1">Treatment group</td><td align="left" rowspan="1" colspan="1">17 Temozolomide+Bevacizumab (42.50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">23 Temozolomide (57.50%)</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold><italic>MRI characteristics (mean and range)</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Pixel spacing (mm)</td><td align="left" rowspan="1" colspan="1">0.67 (0.43&#x02013;1.04)</td></tr><tr><td align="left" rowspan="1" colspan="1">Slice thickness (mm)</td><td align="left" rowspan="1" colspan="1">2.54 (0.80&#x02013;6.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">Slices per patient</td><td align="left" rowspan="1" colspan="1">142 (16&#x02013;301)</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold><italic>Relevant volumetric parameters (mean and range)</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor volume (<italic>V</italic>) (cm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">28.32 (0.99&#x02013;79.23)</td></tr><tr><td align="left" rowspan="1" colspan="1">Contrast enhancing volume (<italic>V</italic><sub>CE</sub>) (cm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">19.99 (0.99&#x02013;68.11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Maximal tumor diameter (cm)</td><td align="left" rowspan="1" colspan="1">5.55 (1.48&#x02013;10.57)</td></tr><tr><td align="left" rowspan="1" colspan="1">Spherical rim width (cm)</td><td align="left" rowspan="1" colspan="1">0.67 (0.25&#x02013;2.07)</td></tr></tbody></table></alternatives></table-wrap><p><xref ref-type="table" rid="pone.0161484.t002">Table 2</xref> lists patients age [<xref rid="pone.0161484.ref025" ref-type="bibr">25</xref>], Performance Status, Barthel index [<xref rid="pone.0161484.ref026" ref-type="bibr">26</xref>], and macroscopic tumor volume [<xref rid="pone.0161484.ref015" ref-type="bibr">15</xref>] for the different subgroups used in this study. There a high similarity between the different groups in terms of classical prognostic variables.</p><table-wrap id="pone.0161484.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.t002</object-id><label>Table 2</label><caption><title>Comparison of classical prognostic biomarkers values between the different patient subgroups.</title></caption><alternatives><graphic id="pone.0161484.t002g" xlink:href="pone.0161484.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Genom009</th><th align="left" rowspan="1" colspan="1">Present study</th><th align="left" rowspan="1" colspan="1">BVZ+ (present study)</th><th align="left" rowspan="1" colspan="1">BVZ- (present study)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Number of patients</bold></td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Median age (Interquartile range) [Interval]</bold></td><td align="left" rowspan="1" colspan="1">63 (13.00)[36, 79]</td><td align="left" rowspan="1" colspan="1">64 (14.50)[36, 74]</td><td align="left" rowspan="1" colspan="1">63 (8.00)[51, 74]</td><td align="left" rowspan="1" colspan="1">64 (15.00)[36, 74]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Average Performance Status(Standard deviation)[Interval]</bold></td><td align="left" rowspan="1" colspan="1">1.09(0.69)[0.0, 2.0]</td><td align="left" rowspan="1" colspan="1">1.00(0.78)[0.0, 2.0]</td><td align="left" rowspan="1" colspan="1">0.82(0.81)[0.0, 2.0]</td><td align="left" rowspan="1" colspan="1">1.13(0.76)[0.0, 2.0]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Average Barthel index(Standard deviation) [Interval]</bold></td><td align="left" rowspan="1" colspan="1">86.89(15.26)[50.0, 100.0]</td><td align="left" rowspan="1" colspan="1">87.25(15.19)[55.0, 100.0]</td><td align="left" rowspan="1" colspan="1">90.00(15.10)[55.0, 100.0]</td><td align="left" rowspan="1" colspan="1">85.22(15.26)[55.0, 100.0]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Average Tumor volume (Standard deviation) [Interval]</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">28.32(23.31)[1.00, 79.23]</td><td align="left" rowspan="1" colspan="1">26.24(25.21)[1.00, 79.23]</td><td align="left" rowspan="1" colspan="1">29.85(22.26)[1.16, 69.18]</td></tr></tbody></table></alternatives></table-wrap><p>The GENOM-009 trial, including centralized review of imaging was approved by the institutional review boards (IRB) of each participating hospital and subsequently countersigned by the IRB of the Hospital Germans Trias i Pujol and approved by Spanish Agency for Medicines and Health Products (Agencia Espa&#x000f1;ola de Medicamentos y Productos Sanitarios, AEMPS). Written informed consent was obtained from all patients before registration. (EUDRACT: 2009-010337-45).</p><sec id="sec008"><title>Image analysis</title><p>The DICOM files were imported into the scientific software package Matlab (R2015b, The MathWorks, Inc., Natick, MA, USA) and pre-processed using a semi-automatic image segmentation procedure. Segmented tumors were manually corrected by an image analysis expert with four years of experience with GBM MRIs.</p></sec><sec id="sec009"><title>Geometrical measures</title><p>After the segmentation, a set of geometrical 3D measures were computed automatically [<xref rid="pone.0161484.ref015" ref-type="bibr">15</xref>]. First, we calculated volumetric measures on the reconstructed tumors: the CE volume (<italic>V</italic><sub><italic>CE</italic></sub>), the volume surrounded by the CE areas or inner volume (<italic>V</italic><sub><italic>I</italic></sub>) and the total postcontrast T1 tumor volume (<italic>V</italic> = <italic>V</italic><sub><italic>CE</italic></sub> + <italic>V</italic><sub><italic>I</italic></sub>). In most of the cases the inner volume corresponds to necrotic areas. Also the maximum tumor diameter in 3D <italic>(d</italic><sub><italic>max</italic></sub> 3D) and some measures of the tumor surface irregularity were computed.</p><p>The average size for the CE rim was called spherical rim width (<italic>&#x003b4;</italic><sub><italic>s</italic></sub>) because it can be obtained from a spherical approximation of the total and CE volume, using the formula
<disp-formula id="pone.0161484.e001"><alternatives><graphic xlink:href="pone.0161484.e001.jpg" id="pone.0161484.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mroot><mml:mrow><mml:mfrac><mml:mn>3</mml:mn><mml:mrow><mml:mn>4</mml:mn><mml:mi>&#x003c0;</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mn>3</mml:mn></mml:mroot><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mroot><mml:mi>V</mml:mi><mml:mn>3</mml:mn></mml:mroot><mml:mo>&#x02212;</mml:mo><mml:mroot><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>I</mml:mi></mml:msub></mml:mrow><mml:mn>3</mml:mn></mml:mroot></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mn>0.62</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mroot><mml:mi>V</mml:mi><mml:mn>3</mml:mn></mml:mroot><mml:mo>&#x02212;</mml:mo><mml:mroot><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>I</mml:mi></mml:msub></mml:mrow><mml:mn>3</mml:mn></mml:mroot></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></p><p>In order to characterize the structure of the CE rim we constructed the surfaces enclosing the CE areas (inner and outer). For every point in these surfaces the minimal distance to the other surface was computed, providing a set of distances, that was used to construct histograms of rim sizes. This histogram was characterized by many measures (median, mean, positions of the quartiles, etc). Of them, the most relevant found was the geometric heterogeneity of the CE rim width (<italic>G</italic><sub><italic>H</italic></sub>). This is defined as the difference between the values of the quartile 4 and 3 of the distribution of the CE rim widths divided by the quartile 4, i.e.</p><disp-formula id="pone.0161484.e002"><alternatives><graphic xlink:href="pone.0161484.e002.jpg" id="pone.0161484.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></disp-formula><p>The geometric heterogeneity uses the difference between the values of quartiles 4 and 3, i.e. the size of the region of the most asymmetric distances of the tumor, divided by the longest rim width in the tumor. This is a normalized measure of the tumor&#x02019;s asymmetry that gets values in the range [0, 1].</p><p><xref ref-type="fig" rid="pone.0161484.g001">Fig 1</xref> shows characteristic slices of two different tumors and the corresponding values of <italic>G</italic><sub><italic>H</italic></sub> obtained for each tumor. The first case (<xref ref-type="fig" rid="pone.0161484.g001">Fig 1A</xref>) corresponds to a heterogeneous tumor with a broad range of distances between the inner zones and the outer part of the CE rim. The second case (<xref ref-type="fig" rid="pone.0161484.g001">Fig 1C</xref>) corresponds to a geometrically more regular tumor. <xref ref-type="fig" rid="pone.0161484.g001">Fig 1B and 1D</xref> show their respective associated histograms of distances, from where the geometrical heterogeneity is computed. The presence of both large and small distances leads to more dispersed histograms, thus larger <italic>G</italic><sub><italic>H</italic></sub> (<xref ref-type="fig" rid="pone.0161484.g001">Fig 1B</xref>). More regular tumors lead to lower dispersion of widths and smaller values of <italic>G</italic><sub><italic>H</italic></sub> (<xref ref-type="fig" rid="pone.0161484.g001">Fig 1D</xref>).</p><fig id="pone.0161484.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.g001</object-id><label>Fig 1</label><caption><title>Visual examples of two tumors with different geometric heterogeneities.</title><p>The first case corresponds to a rim-heterogeneous tumor (Fig 1A and 1B), having large geometric heterogeneity. The second case is a geometrically regular tumor (Fig 1C and 1D), with smaller geometric heterogeneity.</p></caption><graphic xlink:href="pone.0161484.g001"/></fig></sec><sec id="sec010"><title>Heterogeneity measures</title><p>A set of 16 3D heterogeneity textural measures was also computed automatically using Matlab software. The measures considered are based in the classical co-occurrence [<xref rid="pone.0161484.ref027" ref-type="bibr">27</xref>] and run-length matrices [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]. Co-occurrence matrix is a classical tool for heterogeneity computation providing information on <italic>local</italic> heterogeneity by describing the arrangements of pairs of elements (voxels) within the tumor. The run-length matrix characterizes groups of voxels within the tumor to provide information on <italic>regional</italic> heterogeneity. <xref ref-type="table" rid="pone.0161484.t003">Table 3</xref> lists the textural features considered.</p><table-wrap id="pone.0161484.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.t003</object-id><label>Table 3</label><caption><title>Definition of the heterogeneity measures computed in this study.</title></caption><alternatives><graphic id="pone.0161484.t003g" xlink:href="pone.0161484.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Type of measure</th><th align="justify" rowspan="1" colspan="1">Name</th><th align="justify" rowspan="1" colspan="1">Formula</th></tr></thead><tbody><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Co-occurrence matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Entropy [<xref rid="pone.0161484.ref027" ref-type="bibr">27</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e003"><alternatives><graphic id="pone.0161484.e003g" xlink:href="pone.0161484.e003"/><mml:math id="M3"><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mi>C</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>&#x022c5;</mml:mo><mml:mi mathvariant="normal">ln</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Co-occurrence matrix</td><td align="left" rowspan="1" colspan="1">Homogeneity [<xref rid="pone.0161484.ref027" ref-type="bibr">27</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e004"><alternatives><graphic id="pone.0161484.e004g" xlink:href="pone.0161484.e004"/><mml:math id="M4"><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Co-occurrence matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Contrast [<xref rid="pone.0161484.ref027" ref-type="bibr">27</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e005"><alternatives><graphic id="pone.0161484.e005g" xlink:href="pone.0161484.e005"/><mml:math id="M5"><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mi>C</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Co-occurrence matrix</td><td align="left" rowspan="1" colspan="1">Dissimilarity [<xref rid="pone.0161484.ref027" ref-type="bibr">27</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e006"><alternatives><graphic id="pone.0161484.e006g" xlink:href="pone.0161484.e006"/><mml:math id="M6"><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mi>C</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Co-occurrence matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Uniformity [<xref rid="pone.0161484.ref027" ref-type="bibr">27</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e007"><alternatives><graphic id="pone.0161484.e007g" xlink:href="pone.0161484.e007"/><mml:math id="M7"><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Run-length matrix</td><td align="left" rowspan="1" colspan="1">Long Run Emphasis (LRE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e008"><alternatives><graphic id="pone.0161484.e008g" xlink:href="pone.0161484.e008"/><mml:math id="M8"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Run-length matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Short Run Emphasis (SRE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e009"><alternatives><graphic id="pone.0161484.e009g" xlink:href="pone.0161484.e009"/><mml:math id="M9"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Run-length matrix</td><td align="left" rowspan="1" colspan="1">Low Gray-level Run Emphasis (LGRE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e010"><alternatives><graphic id="pone.0161484.e010g" xlink:href="pone.0161484.e010"/><mml:math id="M10"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Run-length matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">High Gray-level Run Emphasis (HGRE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e011"><alternatives><graphic id="pone.0161484.e011g" xlink:href="pone.0161484.e011"/><mml:math id="M11"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Run-length matrix</td><td align="left" rowspan="1" colspan="1">Short Run Low Gray-level Emphasis (SRLRE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e012"><alternatives><graphic id="pone.0161484.e012g" xlink:href="pone.0161484.e012"/><mml:math id="M12"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Run-length matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Short Run High Gray-level Emphasis (SRHGE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e013"><alternatives><graphic id="pone.0161484.e013g" xlink:href="pone.0161484.e013"/><mml:math id="M13"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Run-length matrix</td><td align="left" rowspan="1" colspan="1">Long Run Low Gray-level Emphasis (LRLGE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e014"><alternatives><graphic id="pone.0161484.e014g" xlink:href="pone.0161484.e014"/><mml:math id="M14"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mfrac><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Run-length matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Long Run High Gray-level Emphasis (LRHGE) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e015"><alternatives><graphic id="pone.0161484.e015g" xlink:href="pone.0161484.e015"/><mml:math id="M15"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>&#x022c5;</mml:mo><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Run-length matrix</td><td align="left" rowspan="1" colspan="1">Gray-Level Non-Uniformity (GLNU) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e016"><alternatives><graphic id="pone.0161484.e016g" xlink:href="pone.0161484.e016"/><mml:math id="M16"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Run-length matrix</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1">Run-Length Non-Uniformity (RLNU) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e017"><alternatives><graphic id="pone.0161484.e017g" xlink:href="pone.0161484.e017"/><mml:math id="M17"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Run-length matrix</td><td align="left" rowspan="1" colspan="1">Run Percentage (RPC) [<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>]</td><td align="left" rowspan="1" colspan="1"><inline-formula id="pone.0161484.e018"><alternatives><graphic id="pone.0161484.e018g" xlink:href="pone.0161484.e018"/><mml:math id="M18"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:mi>R</mml:mi><mml:mi>L</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>For CM measures CM(i,j) stands for the co-occurrence matrix, N is the number of classes of gray-levels taken (32 in this study). For RLM measures RLM(i,j) is the run-length matrix, nr is the number of runs, N is the number of classes of gray-levels and M is the size in voxels of the largest region found.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec011"><title>Statistical methods</title><p>To identify geometric parameters associated with prognosis we used Kaplan&#x02013;Meier plots and log-rank analysis. A 2-tailed significance level (p-value) of p&#x0003c;0.05 was applied. We tried to find measures separating patient populations in two groups with significant differences in terms of survival. To do so we: (i) computed the p-values for the full range of thresholds of each variable considered in the study, (ii) accepted only thresholds that separated the populations on reasonably-sized subgroups, and (iii) looked minimum p-values located in low p-value regions of the parameter space (in order to discard purely statistical fluctuations). For each population splitting, we computed the hazard ratio (HR) as an indicator of risk by using a single-variable Cox proportional hazards regression analysis.</p><p>In order to identify measures with similar information, we computed the correlations between the significant variables of the previous analysis. Because of the normality analysis, Spearman's correlation coefficient was considered to study the relation between independent quantitative variables. Correlation coefficient values &#x0003c;0.1 were taking as indicators of no correlation between the variables while values &#x0003e;0.7 were taken as indicators of strong correlation between the variables.</p></sec></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><p>We segmented and geometrically analyzed brain imaging datasets belonging to the 40 patients included in our study (<xref ref-type="table" rid="pone.0161484.t001">Table 1</xref>). By means of Kaplan-Meier analysis, we first compared survival of patients receiving TMZ+BVZ with those only receiving TMZ. While there seems to be a better survival for patients in the TMZ+BVZ arm, the result was statistically non-significant (p = 0.107) for the subset of patients from the Genom009 trial included in this study, what is in line with the clinical trial results.</p><p>Next, we studied the geometrical and heterogeneity measures described in the methods section using Kaplan-Meier curves and Cox proportional hazard analysis. Patients were split into subgroups as described in the methods section. <xref ref-type="table" rid="pone.0161484.t004">Table 4</xref> summarizes the results for the different population splits using the mean, the median and the optimal thresholds used for each significant variable. Thresholds were computed for the BVZ group and then the statistical analysis was performed for both arms.</p><table-wrap id="pone.0161484.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.t004</object-id><label>Table 4</label><caption><title>Summary of univariate Cox and Kaplan-Meier analysis for the more representative variables included in the study.</title><p>Significant results are boldfaced.</p></caption><alternatives><graphic id="pone.0161484.t004g" xlink:href="pone.0161484.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">17 patients (BVZ)</th><th align="center" colspan="2" rowspan="1">23 patients (No BVZ)</th></tr><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">HR, (CI-95%)</th><th align="center" rowspan="1" colspan="1">p-value</th><th align="center" rowspan="1" colspan="1">HR, (CI-95%)</th><th align="center" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold></td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Age (&#x0003c; = 65.00 vs &#x0003e;65.00) (years)</td><td align="right" rowspan="1" colspan="1">2.721 (0.879, 8.425)</td><td align="right" rowspan="1" colspan="1">0.072</td><td align="right" rowspan="1" colspan="1">2.331 (0.864, 6.285)</td><td align="right" rowspan="1" colspan="1">0.084</td></tr><tr><td align="right" rowspan="1" colspan="1">Mean: Age (&#x0003c; = 63.00 vs &#x0003e;63.00) (years)</td><td align="right" rowspan="1" colspan="1">2.485 (0.846, 7.299)</td><td align="right" rowspan="1" colspan="1">0.088</td><td align="right" rowspan="1" colspan="1">1.341 (0.573, 3.138)</td><td align="right" rowspan="1" colspan="1">0.496</td></tr><tr><td align="right" rowspan="1" colspan="1">Median: Age (&#x0003c; = 63.00 vs &#x0003e;63.00) (years)</td><td align="right" rowspan="1" colspan="1">2.485 (0.846, 7.299)</td><td align="right" rowspan="1" colspan="1">0.088</td><td align="right" rowspan="1" colspan="1">1.341 (0.573, 3.138)</td><td align="right" rowspan="1" colspan="1">0.496</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>V</italic><sub><italic>I</italic></sub> (cm<sup>3</sup>) (Necrotic volume)</bold></td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1"><italic>V</italic><sub><italic>I</italic></sub> (&#x0003c; = 2.50 vs &#x0003e;2.50) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1"><bold>4.258 (1.160. 15.635)</bold></td><td align="right" rowspan="1" colspan="1"><bold>0.019</bold></td><td align="right" rowspan="1" colspan="1">2.140 (0.855, 5.361)</td><td align="right" rowspan="1" colspan="1">0.096</td></tr><tr><td align="right" rowspan="1" colspan="1">Mean: <italic>V</italic><sub><italic>I</italic></sub> (&#x0003c; = 7.32 vs &#x0003e;7.32) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1">1.099 (0.389, 3.106)</td><td align="right" rowspan="1" colspan="1">0.858</td><td align="right" rowspan="1" colspan="1">1.843 (0.757, 4.488)</td><td align="right" rowspan="1" colspan="1">0.171</td></tr><tr><td align="right" rowspan="1" colspan="1">Median: <italic>V</italic><sub><italic>I</italic></sub> (&#x0003c; = 4.49 vs &#x0003e;4.49) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1">1.549 (0.552, 4.348)</td><td align="right" rowspan="1" colspan="1">0.402</td><td align="right" rowspan="1" colspan="1">1.843 (0.757, 4.488)</td><td align="right" rowspan="1" colspan="1">0.171</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>V</italic> (cm<sup>3</sup>) (Total volume)</bold></td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1"><italic>V</italic> (&#x0003c; = 5.00 vs &#x0003e;5.00) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1"><bold>4.258 (1.160. 15.635)</bold></td><td align="right" rowspan="1" colspan="1"><bold>0.019</bold></td><td align="right" rowspan="1" colspan="1">1.502 (0.432, 5.228)</td><td align="right" rowspan="1" colspan="1">0.519</td></tr><tr><td align="right" rowspan="1" colspan="1">Mean: <italic>V</italic> (&#x0003c; = 26.24 vs &#x0003e;26.24) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1">1.927 (0.635, 5.850)</td><td align="right" rowspan="1" colspan="1">0.239</td><td align="right" rowspan="1" colspan="1">1.453 (0.615, 3.435)</td><td align="right" rowspan="1" colspan="1">0.391</td></tr><tr><td align="right" rowspan="1" colspan="1">Median: <italic>V</italic> (&#x0003c; = 21.28 vs &#x0003e;21.28)(cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1">2.676 (0.845, 8.471)</td><td align="right" rowspan="1" colspan="1">0.083</td><td align="right" rowspan="1" colspan="1">1.824 (0.749, 4.443)</td><td align="right" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>V</italic><sub><italic>CE</italic></sub> (cm<sup>3</sup>) (CE volume)</bold></td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1"><italic>V</italic><sub><italic>CE</italic></sub> (&#x0003c; = 3.50 vs &#x0003e;3.50) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1"><bold>4.258 (1.160. 15.635)</bold></td><td align="right" rowspan="1" colspan="1"><bold>0.019</bold></td><td align="right" rowspan="1" colspan="1">1.502 (0.432, 5.228)</td><td align="right" rowspan="1" colspan="1">0.519</td></tr><tr><td align="right" rowspan="1" colspan="1">Mean: <italic>V</italic><sub><italic>CE</italic></sub> (&#x0003c; = 18.91 vs &#x0003e;18.91) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1">2.676 (0.845, 8.471)</td><td align="right" rowspan="1" colspan="1">0.083</td><td align="right" rowspan="1" colspan="1">1.288 (0.545, 3.047)</td><td align="right" rowspan="1" colspan="1">0.562</td></tr><tr><td align="right" rowspan="1" colspan="1">Median: <italic>V</italic><sub><italic>CE</italic></sub> (&#x0003c; = 14.40 vs &#x0003e;14.01) (cm<sup>3</sup>)</td><td align="right" rowspan="1" colspan="1"><bold>3.445 (1.008, 11.770)</bold></td><td align="right" rowspan="1" colspan="1"><bold>0.038</bold></td><td align="right" rowspan="1" colspan="1">1.824 (0.749, 4.443)</td><td align="right" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G<sub>H</sub> (Geometric heterogeneity)</bold></td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1"><italic>G</italic><sub><italic>H</italic></sub> (&#x0003c; = 0.605 vs &#x0003e;0.605)</td><td align="right" rowspan="1" colspan="1"><bold>3.931 (1.289, 11.985)</bold></td><td align="right" rowspan="1" colspan="1"><bold>0.011</bold></td><td align="right" rowspan="1" colspan="1">1.070 (0.441, 2.596)</td><td align="right" rowspan="1" colspan="1">0.881</td></tr><tr><td align="right" rowspan="1" colspan="1">Mean: <italic>G</italic><sub><italic>H</italic></sub> (&#x0003c; = 0.608 vs &#x0003e;0.608)</td><td align="right" rowspan="1" colspan="1"><bold>3.050 (1.050. 8.856)</bold></td><td align="right" rowspan="1" colspan="1"><bold>0.032</bold></td><td align="right" rowspan="1" colspan="1">1.070 (0.441, 2.596)</td><td align="right" rowspan="1" colspan="1">0.881</td></tr><tr><td align="right" rowspan="1" colspan="1">Median: <italic>G</italic><sub><italic>H</italic></sub> (&#x0003c; = 0.623 vs &#x0003e;0.623)</td><td align="right" rowspan="1" colspan="1"><bold>3.050 (1.050. 8.856)</bold></td><td align="right" rowspan="1" colspan="1"><bold>0.032</bold></td><td align="right" rowspan="1" colspan="1">1.268 (0.362, 4.438)</td><td align="right" rowspan="1" colspan="1">0.709</td></tr></tbody></table></alternatives></table-wrap><p>The best thresholds for <italic>V</italic>, <italic>V</italic><sub><italic>I</italic></sub>, <italic>V</italic><sub><italic>CE</italic></sub> and <italic>G</italic><sub><italic>H</italic></sub> were found to be 5 cm<sup>3</sup> (p = 0.019), 2.5 cm<sup>3</sup> (p = 0.019), 3.5 cm<sup>3</sup> (p = 0.019) and 0.605 (p = 0.011) respectively (see <xref ref-type="table" rid="pone.0161484.t004">Table 4</xref>). The increases in the median survival times for the favorable subgroups were of 19.72 months (<italic>V</italic>&#x0003c;5 cm<sup>3</sup>, <italic>V</italic><sub><italic>I</italic></sub>&#x0003c;2.5 cm<sup>3</sup> and <italic>V</italic><sub><italic>CE</italic></sub>&#x0003c;3.5 cm<sup>3</sup>) and 19.40 months (<italic>G</italic><sub><italic>H</italic></sub>&#x0003c;0.605). None of the studied image heterogeneity features reached statistical significance.</p><p><xref ref-type="fig" rid="pone.0161484.g002">Fig 2C, 2E, 2G and 2I</xref> show Kaplan-Meier survival curves for the significant variables of our study. The three different volumetric measures considered (<italic>V</italic>, <italic>V</italic><sub><italic>I</italic></sub> and <italic>V</italic><sub><italic>CE</italic></sub>) led to the same population splitting and thus the same Kaplan-Meier curves (shown in <xref ref-type="fig" rid="pone.0161484.g002">Fig 2C, 2E and 2G</xref>). This is due to the limited number of patients in the study and high correlation between the volumetric features. We also show the best threshold for the age (<xref ref-type="fig" rid="pone.0161484.g002">Fig 2A</xref>) although this variable was only marginally significant in our study. In order to discard purely statistical fluctuations, we studied the same computed thresholds on the TMZ only arm. <xref ref-type="fig" rid="pone.0161484.g002">Fig 2B, 2D, 2F, 2H and 2J</xref> show the corresponding Kaplan-Meier survival curves.</p><fig id="pone.0161484.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.g002</object-id><label>Fig 2</label><caption><p>Kaplan-Meier curves for the each significant geometrical variable (plus age, that was marginally significant) using the thresholds of <xref ref-type="table" rid="pone.0161484.t004">Table 4</xref>: (a,b) age, (c,d) <italic>V</italic><sub><italic>I</italic></sub>, (e,f) <italic>V</italic>, (g,h) <italic>V</italic><sub><italic>CE</italic></sub> and (i,j) <italic>G</italic><sub><italic>H</italic></sub>. The median differences, p-values and number of patients per group are indicated in each subplot. Panels (a, c, e, g and i) correspond to patients in the BVZ+TMZ arm while panels (b, d, f, h and j) correspond to the TMZ arm.</p></caption><graphic xlink:href="pone.0161484.g002"/></fig><p>The next step in our analysis was to compare patients having the same geometrical characteristics and study whether BVZ provides any significant benefits. To do so, for each variable found to be significant in the previous analysis, we separated the initial 40 patients between those being above or below the selected best threshold. Then, we used Kaplan-Meier analysis to compare patients in both trial arms. <xref ref-type="fig" rid="pone.0161484.g003">Fig 3</xref> summarizes our results.</p><fig id="pone.0161484.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.g003</object-id><label>Fig 3</label><caption><p>Kaplan-Meier curves comparing survival of subgroups of patients below or above the optimal thresholds shown in <xref ref-type="table" rid="pone.0161484.t004">Table 4</xref>: (a,b) age, (c,d) <italic>V</italic><sub><italic>I</italic></sub>, (e,f) <italic>V</italic>, (g,h) <italic>V</italic><sub><italic>CE</italic></sub> and (i,j) <italic>G</italic><sub><italic>H</italic></sub>. The median differences, p-values and number of patients in each subgroup are indicated.</p></caption><graphic xlink:href="pone.0161484.g003"/></fig><p>The outstanding feature of this analysis was the contrast enhancing rim geometric heterogeneity <italic>G</italic><sub><italic>H</italic></sub> (<xref ref-type="fig" rid="pone.0161484.g003">Fig 3I and 3J</xref>). Patients having a small <italic>G</italic><sub><italic>H</italic></sub> had a significant strong benefit from BVZ (<italic>p</italic> = 0.011, <xref ref-type="fig" rid="pone.0161484.g003">Fig 3I</xref>) with a median survival difference of 15.88 months. On the other hand, patients with large <italic>G</italic><sub><italic>H</italic></sub> (<italic>p</italic> = 0.930. <xref ref-type="fig" rid="pone.0161484.g003">Fig 3J</xref>) did not present any benefit from BVZ.</p><p>The necrotic volume <italic>V</italic><sub><italic>I</italic></sub> also showed significant results in terms of survival (<xref ref-type="fig" rid="pone.0161484.g003">Fig 3C and 3D</xref>). Patients having a small <italic>V</italic><sub><italic>I</italic></sub> strongly benefited from BVZ (<italic>p</italic> = 0.047, <xref ref-type="fig" rid="pone.0161484.g003">Fig 3C</xref>) with a median survival of 15.52 months. On the other hand, patients with large <italic>V</italic><sub><italic>I</italic></sub> (<italic>p</italic> = 0.328. <xref ref-type="fig" rid="pone.0161484.g003">Fig 3D</xref>) did not present any benefit from BVZ.</p><p>As next step, we computed the Spearman&#x02019;s correlation coefficient and the associated p between all significant variables (<xref ref-type="table" rid="pone.0161484.t005">Table 5</xref>). It is relevant to point out that the volumetric variables (<italic>V</italic><sub><italic>CE</italic></sub>, <italic>V</italic><sub><italic>I</italic></sub>, <italic>V</italic>) were mutually correlated and weakly (but significantly in most cases) correlated with the geometric heterogeneity <italic>G</italic><sub><italic>H</italic></sub>.</p><table-wrap id="pone.0161484.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.t005</object-id><label>Table 5</label><caption><title>Spearman correlation coefficients between every pair of significant variables in our study.</title><p>Boldfaced numbers indicate significant correlations (p&#x0003c;0.05).</p></caption><alternatives><graphic id="pone.0161484.t005g" xlink:href="pone.0161484.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="justify" rowspan="1" colspan="1"><italic>V</italic><sub><italic>I</italic></sub></th><th align="justify" rowspan="1" colspan="1"><italic>V</italic></th><th align="justify" rowspan="1" colspan="1"><italic>V</italic><sub><italic>CE</italic></sub></th><th align="justify" rowspan="1" colspan="1">G<sub>H</sub></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>V<sub>I</sub></italic></bold></td><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.790</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.670</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.522</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>V</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.963</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.322</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>V<sub>CE</sub></italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.253</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G</bold><sub><bold>H</bold></sub></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>1</bold></td></tr></tbody></table></alternatives></table-wrap><p><xref ref-type="table" rid="pone.0161484.t006">Table 6</xref> shows the computed values of the geometric heterogeneity and the necrotic volumes for all patients included in this study, together with their overall survival and O(6)-Methylguanine-DNA-methyltransferase (MGMT) status. Patients in the first part of the table (those taking only TMZ) having large overall survival could be mostly identified by the presence of the MGMT methilation, due to its relation with the response to temozolomide. On the other hand, patients in the BVZ group (second part of <xref ref-type="table" rid="pone.0161484.t006">Table 6</xref>) with long survivals were strongly identified by <italic>G</italic><sub><italic>H</italic></sub>.</p><table-wrap id="pone.0161484.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161484.t006</object-id><label>Table 6</label><caption><title>Overall survival, <italic>G</italic><sub><italic>H</italic></sub>, <italic>V</italic><sub><italic>I</italic></sub> and MGMT status (when available) for all of the patients included in the study.</title><p>Within each group (BVZ+ or BVZ-) patients are ordered by survival. Grey cells indicate patients in the favourable groups: either small <italic>G</italic><sub><italic>H</italic></sub> (dark grey) or unmethilated MGMT (light grey).</p></caption><alternatives><graphic id="pone.0161484.t006g" xlink:href="pone.0161484.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">BVZ-</th><th align="center" colspan="2" rowspan="1"/><th align="center" colspan="3" rowspan="1">BVZ+</th></tr><tr><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">OS</th><th align="center" rowspan="1" colspan="1"><italic>V</italic><sub><italic>I</italic></sub></th><th align="center" rowspan="1" colspan="1"><italic>G</italic><sub><italic>H</italic></sub></th><th align="center" rowspan="1" colspan="1">MGMT</th><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">OS</th><th align="center" rowspan="1" colspan="1"><italic>V</italic><sub><italic>I</italic></sub></th><th align="center" rowspan="1" colspan="1"><italic>G</italic><sub><italic>H</italic></sub></th><th align="center" rowspan="1" colspan="1">MGMT</th></tr></thead><tbody><tr><td align="right" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">70</td><td align="right" rowspan="1" colspan="1">14.182</td><td align="right" rowspan="1" colspan="1">0.611</td><td align="right" style="background-color:#D9D9D9" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">24</td><td align="right" rowspan="1" colspan="1">72</td><td align="right" rowspan="1" colspan="1">2.979</td><td align="right" rowspan="1" colspan="1">0.752</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">2</td><td align="right" rowspan="1" colspan="1">71</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.070</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.444</td><td align="right" rowspan="1" colspan="1">-</td><td align="right" rowspan="1" colspan="1">25</td><td align="right" rowspan="1" colspan="1">121</td><td align="right" rowspan="1" colspan="1">4.135</td><td align="right" rowspan="1" colspan="1">0.623</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="right" rowspan="1" colspan="1">3</td><td align="right" rowspan="1" colspan="1">71</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.439</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.292</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">26</td><td align="right" rowspan="1" colspan="1">128</td><td align="right" rowspan="1" colspan="1">3.866</td><td align="right" rowspan="1" colspan="1">0.635</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">4</td><td align="right" rowspan="1" colspan="1">82</td><td align="right" rowspan="1" colspan="1">39.114</td><td align="right" rowspan="1" colspan="1">0.719</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">27</td><td align="right" rowspan="1" colspan="1">131</td><td align="right" rowspan="1" colspan="1">12.598</td><td align="right" rowspan="1" colspan="1">0.607</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="right" rowspan="1" colspan="1">5</td><td align="right" rowspan="1" colspan="1">86</td><td align="right" rowspan="1" colspan="1">8.699</td><td align="right" rowspan="1" colspan="1">0.609</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">28</td><td align="right" rowspan="1" colspan="1">213</td><td align="right" rowspan="1" colspan="1">6.401</td><td align="right" rowspan="1" colspan="1">0.792</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">6</td><td align="right" rowspan="1" colspan="1">102</td><td align="right" rowspan="1" colspan="1">3.640</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.562</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">29</td><td align="right" rowspan="1" colspan="1">294</td><td align="right" rowspan="1" colspan="1">6.875</td><td align="right" rowspan="1" colspan="1">0.633</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">7</td><td align="right" rowspan="1" colspan="1">126</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">1.422</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.395</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">30</td><td align="right" rowspan="1" colspan="1">311</td><td align="right" rowspan="1" colspan="1">30.054</td><td align="right" rowspan="1" colspan="1">0.721</td><td align="right" rowspan="1" colspan="1">-</td></tr><tr><td align="right" rowspan="1" colspan="1">8</td><td align="right" rowspan="1" colspan="1">132</td><td align="right" rowspan="1" colspan="1">8.243</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.572</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">31</td><td align="right" rowspan="1" colspan="1">336</td><td align="right" rowspan="1" colspan="1">19.244</td><td align="right" rowspan="1" colspan="1">0.698</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="right" rowspan="1" colspan="1">9</td><td align="right" rowspan="1" colspan="1">144</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">2.384</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.467</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">32</td><td align="right" rowspan="1" colspan="1">395</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.220</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.588</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="right" rowspan="1" colspan="1">10</td><td align="right" rowspan="1" colspan="1">176</td><td align="right" rowspan="1" colspan="1">10.236</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.589</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">33</td><td align="right" rowspan="1" colspan="1">416</td><td align="right" rowspan="1" colspan="1">4.486</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.544</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">11</td><td align="right" rowspan="1" colspan="1">227</td><td align="right" rowspan="1" colspan="1">16.513</td><td align="right" rowspan="1" colspan="1">0.621</td><td align="right" rowspan="1" colspan="1">-</td><td align="right" rowspan="1" colspan="1">34</td><td align="right" rowspan="1" colspan="1">511</td><td align="right" rowspan="1" colspan="1">11.819</td><td align="right" rowspan="1" colspan="1">0.662</td><td align="right" rowspan="1" colspan="1">-</td></tr><tr><td align="right" rowspan="1" colspan="1">12</td><td align="right" rowspan="1" colspan="1">245</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">2.349</td><td align="right" rowspan="1" colspan="1">0.646</td><td align="right" rowspan="1" colspan="1">-</td><td align="right" rowspan="1" colspan="1">35</td><td align="right" rowspan="1" colspan="1">683</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.011</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.368</td><td align="right" rowspan="1" colspan="1">-</td></tr><tr><td align="right" rowspan="1" colspan="1">13</td><td align="right" rowspan="1" colspan="1">320</td><td align="right" rowspan="1" colspan="1">14.882</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.505</td><td align="right" rowspan="1" colspan="1">-</td><td align="right" rowspan="1" colspan="1">36</td><td align="right" rowspan="1" colspan="1">803</td><td align="right" rowspan="1" colspan="1">11.677</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.531</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">14</td><td align="right" rowspan="1" colspan="1">375</td><td align="right" rowspan="1" colspan="1">30.470</td><td align="right" rowspan="1" colspan="1">0.623</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">37</td><td align="right" rowspan="1" colspan="1">894</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">1.884</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.601</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">15</td><td align="right" rowspan="1" colspan="1">416</td><td align="right" rowspan="1" colspan="1">3.695</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.453</td><td align="right" style="background-color:#D9D9D9" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">38</td><td align="right" rowspan="1" colspan="1">932</td><td align="right" rowspan="1" colspan="1">7.473</td><td align="right" rowspan="1" colspan="1">0.723</td><td align="right" rowspan="1" colspan="1">-</td></tr><tr><td align="right" rowspan="1" colspan="1">16</td><td align="right" rowspan="1" colspan="1">422</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.872</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.539</td><td align="right" style="background-color:#D9D9D9" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">39</td><td align="right" rowspan="1" colspan="1">1363</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.093</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.346</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">17</td><td align="right" rowspan="1" colspan="1">453</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.054</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.235</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">40</td><td align="right" rowspan="1" colspan="1">1592</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.682</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.509</td><td align="right" style="background-color:#E7E6E6" rowspan="1" colspan="1">1</td></tr><tr><td align="right" rowspan="1" colspan="1">18</td><td align="right" rowspan="1" colspan="1">494</td><td align="right" rowspan="1" colspan="1">26.232</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.589</td><td align="right" style="background-color:#D9D9D9" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">19</td><td align="right" rowspan="1" colspan="1">533</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">1.527</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.412</td><td align="right" style="background-color:#D9D9D9" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">20</td><td align="right" rowspan="1" colspan="1">584</td><td align="right" rowspan="1" colspan="1">20.928</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.581</td><td align="right" rowspan="1" colspan="1">-</td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">21</td><td align="right" rowspan="1" colspan="1">629</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.825</td><td align="right" rowspan="1" colspan="1">0.610</td><td align="right" rowspan="1" colspan="1">-</td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">22</td><td align="right" rowspan="1" colspan="1">909</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">0.353</td><td align="right" rowspan="1" colspan="1">0.725</td><td align="right" rowspan="1" colspan="1">-</td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">23</td><td align="right" rowspan="1" colspan="1">1205</td><td align="right" style="background-color:#D0CECE" rowspan="1" colspan="1">1.546</td><td align="right" style="background-color:#BFBFBF" rowspan="1" colspan="1">0.402</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>Personalized medicine is becoming one of the major research topics in medicine and specifically in oncology [<xref rid="pone.0161484.ref029" ref-type="bibr">29</xref>]. Researchers have discovered genes that harbor variations contributing to human cancers, identified genetic variability in patients&#x02019; responses to different treatments, and begun to target the causes of some tumors. This requires the use of diagnostic tests able to predict patients&#x02019; responses to the therapies. Imaging biomarkers in different types of cancers [<xref rid="pone.0161484.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0161484.ref031" ref-type="bibr">31</xref>] and specifically in GBM [<xref rid="pone.0161484.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0161484.ref033" ref-type="bibr">33</xref>] are receiving a lot of attention recently as an alternative or complement to the more &#x02018;standard&#x02019; tests based on genetics or other molecular mechanisms.</p><p>Experimental data indicate that the most important angiogenic signaling pathway in gliomas involves the vascular endothelial growth factor (VEGF) and its receptor VEGFR-2. BVZ is a human recombinant monoclonal antibody specific for the VEGF ligand that is being used to treat recurrent GBM in spite of the scarcity of direct evidence of increased survival with such treatment compared to other existing alternatives [<xref rid="pone.0161484.ref034" ref-type="bibr">34</xref>].</p><p>Imaging biomarkers have been found in GBM to determine prognosis [<xref rid="pone.0161484.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0161484.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0161484.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0161484.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0161484.ref035" ref-type="bibr">35</xref>] and to assess the response to antiangiogenic therapies [<xref rid="pone.0161484.ref036" ref-type="bibr">36</xref>]. Specifically, to distinguish progression from pseudoprogression or to provide early indications of treatment response in recurrent GBMs [<xref rid="pone.0161484.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0161484.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0161484.ref031" ref-type="bibr">31</xref>].</p><p>Our goal in this study was to test if a set of geometrical [<xref rid="pone.0161484.ref015" ref-type="bibr">15</xref>] and heterogeneity [<xref rid="pone.0161484.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0161484.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0161484.ref028" ref-type="bibr">28</xref>] features obtained from pretreatment postcontrast T1 weighted MRIs, some of them found previously to have a prognostic value, were predictors of response to antiangiogenic therapies.</p><p>When the group of patients receiving BVZ was considered, and for several geometrical variables, we found thresholds splitting this group into subgroups with significant differences in survival. When the same threshold was found to split the population of patients receiving only TMZ there were no significant differences between both subgroups. This means that the thresholds found are not just indicating a better prognosis group for the whole GBM patient population but instead reflecting a different response to the therapy in the different groups.</p><p>The analysis developed points out to two geometric parameters: the necrotic volume <italic>V</italic><sub><italic>I</italic></sub> and the geometric heterogeneity <italic>G</italic><sub><italic>H</italic></sub> as potential predictors of BVZ effectivity. Due to the limited number of patients available <italic>V</italic><sub><italic>I</italic></sub> was only marginally significant what points out the need for further prospective studies.</p><p>It is remarkable that patients with small values of the geometric heterogeneity of the contrast enhancing rim, in many cases being the same ones as those with small necrotic volumes, were the ones having more benefits from therapy. These tumors (small <italic>G</italic><sub><italic>H</italic></sub> and <italic>V</italic><sub><italic>I</italic></sub>) display uniform contrast enhancement and small necrotic cores with rounded shapes. It has been demonstrated using mathematical models that that harsh tumor microenvironment conditions exert a dramatic selective force on the tumor, which grows as an invasive mass with fingering margins, dominated by a few clones with aggressive traits [<xref rid="pone.0161484.ref037" ref-type="bibr">37</xref>]. In the specific case of GBM those conditions arise after hypoxic events, that lead to the generation of necrotic areas and the acceleration of tumor growth and the development of more aggressive and infiltrative phenotypes [<xref rid="pone.0161484.ref038" ref-type="bibr">38</xref>,<xref rid="pone.0161484.ref039" ref-type="bibr">39</xref>]. Thus, in line with recent mathematical models [<xref rid="pone.0161484.ref014" ref-type="bibr">14</xref>], we think that these tumors are probably in the early steps of their natural history and are still more dependent on angiogenesis for their development.</p><p>In contrast, mild microenvironment conditions allow clones with similar aggressive traits to coexist with less aggressive phenotypes in a heterogeneous tumor mass with smooth, noninvasive margins [<xref rid="pone.0161484.ref037" ref-type="bibr">37</xref>]. Thus, the genetic make-up of a cancer cell may realize its invasive potential through a clonal evolution process driven by definable microenvironmental selective forces. The presence of necrosis and/or large values of the geometric heterogeneity would be a macroscopic reflection of these microscopic processes.</p><p>Indeed, the mesenchimal GBM subtype is known to generate large necrotic areas, have higher infiltration and could be less dependent on angiogenesis than tumors with the proliferative molecular subtype [<xref rid="pone.0161484.ref040" ref-type="bibr">40</xref>]. For our patients genomic data was not available but it would be very interesting to correlate these macroscopic features with genomic data on the light of the GBM molecular classification.</p><p>As mentioned before, the main limitation of our study is the small number of patients, due to the restrictive inclusion criteria imposed. Specifically, high resolution images (3D T1) are necessary to obtain reliable values for the geometrical parameters in general and very specifically to compute <italic>G</italic><sub><italic>H</italic></sub>. This is why Genom009 was a good candidate trial to include its patients in our study, since neoadjuvant treatment (BEV and TMZ or TMZ) was administered as first-line treatment before radiotherapy, thus, removing the effects of radiotherapy over the blood brain barrier that produce secondary changes in contrast enhancement and difficult the response assessment as the study was performed over basal, pretreatment MRI. A prospective study design with high resolution images, in agreement with current recommendations [<xref rid="pone.0161484.ref041" ref-type="bibr">41</xref>], is necessary to confirm the potential clinical applicability of the imaging biomarkers defined here.</p></sec><sec sec-type="conclusions" id="sec014"><title>Conclusions</title><p>Two geometrical features obtained from high resolution postcontrast and pretreatment MRI T1-weighted images were predictive of benefit from BVZ: the geometric heterogeneity of the contrast-enhancing rim and the necrotic volume. Our results suggest that this drug may have a substantial potential benefit on a subset of patients with tumors having regular geometries or very small necrotic volumes. The measurement, study and validation of these characteristics may be key to plan treatment and predict response and evolution of GBM patients. A prospective study is necessary to corroborate our results.</p></sec></body><back><ack><p>We would like to acknowledge Juan Belmonte (Universidad de Castilla-La Mancha) for discussions. The authors declare no conflict of interests.</p></ack><ref-list><title>References</title><ref id="pone.0161484.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Stupp</surname><given-names>R</given-names></name>, <name><surname>Mason</surname><given-names>WP</given-names></name>, <name><surname>van den Bent</surname><given-names>MJ</given-names></name>, <name><surname>Weller</surname><given-names>M</given-names></name>, <name><surname>Ficher</surname><given-names>B</given-names></name>, <name><surname>Taphoorn</surname><given-names>MJB</given-names></name>, <etal>et al</etal>
<article-title>Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma</article-title>, <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>987</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="pmid">15758009</pub-id></mixed-citation></ref><ref id="pone.0161484.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Weathers</surname><given-names>SP</given-names></name>, <name><surname>de Groot</surname><given-names>J</given-names></name>. <article-title>VEGF manipulation in glioblastoma</article-title>, <source>Oncology</source>. <year>2015</year>;<volume>29</volume>:<fpage>720</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="pmid">26470893</pub-id></mixed-citation></ref><ref id="pone.0161484.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Chinot</surname><given-names>OL</given-names></name>, <name><surname>Wick</surname><given-names>W</given-names></name>, <name><surname>Mason</surname><given-names>W</given-names></name>, <name><surname>Henriksson</surname><given-names>R</given-names></name>, <name><surname>Saran</surname><given-names>F</given-names></name>, <name><surname>Nishikawa</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>:<fpage>709</fpage>&#x02013;<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1308345">10.1056/NEJMoa1308345</ext-link></comment>
<pub-id pub-id-type="pmid">24552318</pub-id></mixed-citation></ref><ref id="pone.0161484.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Gilbert</surname><given-names>MR</given-names></name>, <name><surname>Dignam</surname><given-names>JJ</given-names></name>, <name><surname>Armstrong</surname><given-names>TS</given-names></name>, <name><surname>Wefel</surname><given-names>JS</given-names></name>, <name><surname>Blumenthal</surname><given-names>DT</given-names></name>, <name><surname>Vogelbaum</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>A randomized trial of bevacizumab for newly diagnosed glioblastoma</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>:<fpage>699</fpage>&#x02013;<lpage>708</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1308573">10.1056/NEJMoa1308573</ext-link></comment>
<pub-id pub-id-type="pmid">24552317</pub-id></mixed-citation></ref><ref id="pone.0161484.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Wick</surname><given-names>W</given-names></name>, <name><surname>Brander</surname><given-names>A</given-names></name>, <name><surname>Gorlia</surname><given-names>T</given-names></name>, <name><surname>Bendszus</surname><given-names>M</given-names></name>, <name><surname>Sahm</surname><given-names>F</given-names></name>, <name><surname>Taal</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial</article-title>. <source>Neuro Oncol</source>. <year>2015</year>;<volume>17</volume>
<issue>Suppl 5</issue>:<fpage>v1</fpage>&#x02013;<lpage>v1</lpage>.</mixed-citation></ref><ref id="pone.0161484.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Prados</surname><given-names>M</given-names></name>, <name><surname>Cloughesy</surname><given-names>T</given-names></name>, <name><surname>Samant</surname><given-names>M</given-names></name>, <name><surname>Fang</surname><given-names>L</given-names></name>, <name><surname>Wen</surname><given-names>PY</given-names></name>, <name><surname>Mikkelsen</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab</article-title>. <source>Neuro Oncol</source>. <year>2011</year>;<volume>13</volume>:<fpage>143</fpage>&#x02013;<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/neuonc/noq151">10.1093/neuonc/noq151</ext-link></comment>
<pub-id pub-id-type="pmid">21084434</pub-id></mixed-citation></ref><ref id="pone.0161484.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>DR</given-names></name>, <name><surname>Leeper</surname><given-names>HE</given-names></name>, <name><surname>Uhm</surname><given-names>JH</given-names></name>. <article-title>Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis</article-title>. <source>Cancer</source>. <year>2013</year>;<volume>119</volume>:<fpage>3489</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.28259">10.1002/cncr.28259</ext-link></comment>
<pub-id pub-id-type="pmid">23868553</pub-id></mixed-citation></ref><ref id="pone.0161484.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Sandmann</surname><given-names>T</given-names></name>, <name><surname>Bourgon</surname><given-names>R</given-names></name>, <name><surname>Garcia</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Cloughesy</surname><given-names>T</given-names></name>, <name><surname>Chinot</surname><given-names>OL</given-names></name>, <etal>et al</etal>
<article-title>Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio Trial</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>:<fpage>2735</fpage>&#x02013;<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2015.61.5005">10.1200/JCO.2015.61.5005</ext-link></comment>
<pub-id pub-id-type="pmid">26124478</pub-id></mixed-citation></ref><ref id="pone.0161484.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Erdem-Eraslan</surname><given-names>L</given-names></name>, <name><surname>van den Bent</surname><given-names>MJ</given-names></name>, <name><surname>Hoogstrate</surname><given-names>Y</given-names></name>, <name><surname>Naz-Khan</surname><given-names>H</given-names></name>, <name><surname>Stubbs</surname><given-names>A</given-names></name>, <name><surname>van der Spek</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial</article-title>. <source>Cancer Res</source>. <year>2016</year>;<volume>76</volume>:<fpage>525</fpage>&#x02013;<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-15-0776">10.1158/0008-5472.CAN-15-0776</ext-link></comment>
<pub-id pub-id-type="pmid">26762204</pub-id></mixed-citation></ref><ref id="pone.0161484.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Pope</surname><given-names>WB</given-names></name>, <name><surname>Kim</surname><given-names>HJ</given-names></name>, <name><surname>Huo</surname><given-names>J</given-names></name>, <name><surname>Alger</surname><given-names>J</given-names></name>, <name><surname>Brown</surname><given-names>MS</given-names></name>, <name><surname>Gjertson</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment</article-title>. <source>Radiology</source>. <year>2009</year>;<volume>252</volume>:<fpage>182</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1148/radiol.2521081534">10.1148/radiol.2521081534</ext-link></comment>
<pub-id pub-id-type="pmid">19561256</pub-id></mixed-citation></ref><ref id="pone.0161484.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Lu-Emerson</surname><given-names>C</given-names></name>, <name><surname>Duda</surname><given-names>DG</given-names></name>, <name><surname>Emblem</surname><given-names>KE</given-names></name>, <name><surname>Taylor</surname><given-names>JW</given-names></name>, <name><surname>Gerstner</surname><given-names>ER</given-names></name>, <name><surname>Loeffler</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with Glioblastoma</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>:<fpage>1197</fpage>&#x02013;<lpage>213</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2014.55.9575">10.1200/JCO.2014.55.9575</ext-link></comment>
<pub-id pub-id-type="pmid">25713439</pub-id></mixed-citation></ref><ref id="pone.0161484.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Aquino</surname><given-names>D</given-names></name>, <name><surname>Di Stefano</surname><given-names>AL</given-names></name>, <name><surname>Scotti</surname><given-names>A</given-names></name>, <name><surname>Cuppini</surname><given-names>L</given-names></name>, <name><surname>Anghileri</surname><given-names>E</given-names></name>, <name><surname>Finocchiaro</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan</article-title>. <source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>:<fpage>e90535</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0090535">10.1371/journal.pone.0090535</ext-link></comment>
<pub-id pub-id-type="pmid">24675671</pub-id></mixed-citation></ref><ref id="pone.0161484.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Pope</surname><given-names>WB</given-names></name>. <article-title>Evidence for rCBV as an early response marker following bevacizumab treatment</article-title>. <source>Neuro Oncol</source>. <year>2015</year>;<volume>17</volume>:<fpage>1539</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/neuonc/nov199">10.1093/neuonc/nov199</ext-link></comment>
<pub-id pub-id-type="pmid">26453577</pub-id></mixed-citation></ref><ref id="pone.0161484.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>VM</given-names></name>, <name><surname>Calvo</surname><given-names>GF</given-names></name>, <name><surname>Belmonte-Beitia</surname><given-names>J</given-names></name>, <name><surname>Diego</surname><given-names>D</given-names></name>, <name><surname>P&#x000e9;rez-Romasanta</surname><given-names>LA</given-names></name>. <article-title>Bright solitary waves in malignant gliomas</article-title>. <source>Phys Rev E</source>. <year>2011</year>;<volume>84</volume>:<fpage>021921</fpage>.</mixed-citation></ref><ref id="pone.0161484.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>P&#x000e9;rez-Beteta</surname><given-names>J</given-names></name>, <name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>A</given-names></name>, <name><surname>Molina</surname><given-names>D</given-names></name>, <name><surname>Amo-Salas</surname><given-names>M</given-names></name>, <name><surname>Luque</surname><given-names>B</given-names></name>, <name><surname>Arregui</surname><given-names>E</given-names></name>
<etal>et al</etal>
<article-title>Glioblastoma: Does the pretreatment geometry matter? A postcontrast T1 MRI-based study</article-title>. <source>Eur Radiol</source>. <year>2016</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00330-016-4453-9">10.1007/s00330-016-4453-9</ext-link></comment></mixed-citation></ref><ref id="pone.0161484.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Mazurowski</surname><given-names>MA</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Peters</surname><given-names>KB</given-names></name>, <name><surname>Hobbs</surname><given-names>H</given-names></name>. <article-title>Computer extracted MR imaging features are associated with survival in glioblastoma patients</article-title>. <source>J Neurooncol</source>. <year>2014</year>;<volume>120</volume>:<fpage>483</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11060-014-1580-5">10.1007/s11060-014-1580-5</ext-link></comment>
<pub-id pub-id-type="pmid">25151504</pub-id></mixed-citation></ref><ref id="pone.0161484.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Zinn</surname><given-names>PO</given-names></name>, <name><surname>Sathyan</surname><given-names>P</given-names></name>, <name><surname>Mahajan</surname><given-names>B</given-names></name>, <name><surname>Bruyere</surname><given-names>J</given-names></name>, <name><surname>Hegi</surname><given-names>M</given-names></name>, <name><surname>Majumder</surname><given-names>S</given-names></name>
<etal>et al</etal>
<article-title>A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e41522</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0041522">10.1371/journal.pone.0041522</ext-link></comment>
<pub-id pub-id-type="pmid">22870228</pub-id></mixed-citation></ref><ref id="pone.0161484.ref018"><label>18</label><mixed-citation publication-type="other">Upadhaya T, Morvan Y, Stindel E, Le Reste PJ, Hatt M. Prognostic value of multimodal MRI tumour features in Glioblastoma multiforme using textural features analysis. Biomedical Imaging IEEE 12th International Symposium. 2015; 50&#x02013;4.</mixed-citation></ref><ref id="pone.0161484.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Molina</surname><given-names>D</given-names></name>, <name><surname>P&#x000e9;rez-Beteta</surname><given-names>J</given-names></name>, <name><surname>Luque</surname><given-names>B</given-names></name>, <name><surname>Arregui</surname><given-names>E</given-names></name>, <name><surname>Calvo</surname><given-names>M</given-names></name>, <name><surname>Borr&#x000e1;s</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival</article-title>. <source>British Journal of Radiology</source>
<year>2016</year>; <volume>86</volume>, <fpage>20160242</fpage><pub-id pub-id-type="pmid">27319577</pub-id></mixed-citation></ref><ref id="pone.0161484.ref020"><label>20</label><mixed-citation publication-type="other">Chaddad A, Zinn PO, Colen RR. Quantitative Texture Analysis for Glioblastoma Phenotypes Discrimination. International Conference on Control, Decision and Information Technologies (CoDIT). 2014; 605&#x02013;8.</mixed-citation></ref><ref id="pone.0161484.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Ryu</surname><given-names>YJ</given-names></name>, <name><surname>Choi</surname><given-names>SH</given-names></name>, <name><surname>Park</surname><given-names>SJ</given-names></name>, <name><surname>Yun</surname><given-names>TJ</given-names></name>, <name><surname>Kim</surname><given-names>J-H</given-names></name>, <name><surname>Sohn</surname><given-names>C-H</given-names></name>. <article-title>Glioma: Application of Whole-Tumour Texture Analysis of Diffusion-Weighted Imaging for the Evaluation of Tumour Heterogeneity</article-title>. <source>PLoS ONE</source>. <year>2014</year>; <volume>9</volume>: <fpage>e108335</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0108335">10.1371/journal.pone.0108335</ext-link></comment>
<pub-id pub-id-type="pmid">25268588</pub-id></mixed-citation></ref><ref id="pone.0161484.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Resmi</surname><given-names>A</given-names></name>, <name><surname>Tessamma</surname><given-names>T</given-names></name>. <article-title>Automatic Detection and Classification of Glioma Tumours using Statistical Features</article-title>. <source>Int Jl Emerging Technol</source>. <year>2014</year>; <volume>7</volume>:<fpage>8</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="pone.0161484.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Balana</surname><given-names>C</given-names></name>, <name><surname>De Las Penas</surname><given-names>R</given-names></name>, <name><surname>Sepulveda</surname><given-names>JM</given-names></name>, <name><surname>Gil-Gil</surname><given-names>MJ</given-names></name>, <name><surname>Luque</surname><given-names>R</given-names></name>, <name><surname>Gallego</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM009 randomized phase II trial</article-title>. <source>J Neuro Oncol</source>. <year>2016</year>;<volume>127</volume>:<fpage>569</fpage>&#x02013;<lpage>79</lpage>.</mixed-citation></ref><ref id="pone.0161484.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Wen</surname><given-names>PY</given-names></name>, <name><surname>Macdonald</surname><given-names>DR</given-names></name>, <name><surname>Reardon</surname><given-names>DA</given-names></name>, <name><surname>Cloughesy</surname><given-names>TF</given-names></name>, <name><surname>Sorensen</surname><given-names>AG</given-names></name>, <name><surname>Galanis</surname><given-names>E</given-names></name>
<etal>et al</etal>
<article-title>Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>1963</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2009.26.3541">10.1200/JCO.2009.26.3541</ext-link></comment>
<pub-id pub-id-type="pmid">20231676</pub-id></mixed-citation></ref><ref id="pone.0161484.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Lamborn</surname><given-names>KR</given-names></name>, <name><surname>Chang</surname><given-names>SM</given-names></name>, <name><surname>Prados</surname><given-names>MD</given-names></name>. <article-title>Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis</article-title>. <source>Neuro-Oncology</source>. <year>2004</year>;<volume>6</volume>:<fpage>227</fpage>&#x02013;<lpage>235</lpage>. <pub-id pub-id-type="pmid">15279715</pub-id></mixed-citation></ref><ref id="pone.0161484.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Flechl</surname><given-names>B</given-names></name>, <name><surname>Ackerl</surname><given-names>M</given-names></name>, <name><surname>Sax</surname><given-names>C</given-names></name>, <name><surname>Dieckman</surname><given-names>K</given-names></name>, <name><surname>Crevenna</surname><given-names>R</given-names></name>, <name><surname>Gaiger</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors</article-title>. <source>J Neurooncol</source>. <year>2012</year>; <volume>109</volume>:<fpage>331</fpage>&#x02013;<lpage>339</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11060-012-0897-1">10.1007/s11060-012-0897-1</ext-link></comment>
<pub-id pub-id-type="pmid">22644537</pub-id></mixed-citation></ref><ref id="pone.0161484.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Tixier</surname><given-names>F</given-names></name>, <name><surname>Hatt</surname><given-names>M</given-names></name>, <name><surname>Le Rest</surname><given-names>CC</given-names></name>, <name><surname>Le Pogam</surname><given-names>A</given-names></name>, <name><surname>Corcos</surname><given-names>L</given-names></name>, <name><surname>Visvikis</surname><given-names>D</given-names></name>. <article-title>Reproducibility of tumour putake heterogeneity characterization through textural feature analysis in 18f-fdg pet imaging</article-title>. <source>J Nucl Med</source>. <year>2012</year>; <volume>53</volume>(<issue>5</issue>):<fpage>693</fpage>&#x02013;<lpage>700</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.111.099127">10.2967/jnumed.111.099127</ext-link></comment>
<pub-id pub-id-type="pmid">22454484</pub-id></mixed-citation></ref><ref id="pone.0161484.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Tixier</surname><given-names>F</given-names></name>, <name><surname>Le Rest</surname><given-names>CC</given-names></name>, <name><surname>Hat</surname><given-names>M</given-names></name>, <name><surname>Algarghach</surname><given-names>N</given-names></name>, <name><surname>Pradier</surname><given-names>O</given-names></name>, <name><surname>Metges</surname><given-names>JP</given-names></name>
<etal>et al</etal>
<article-title>Intratumour heterogeneity characterized by textural features on baseline 18F-FDT PET images predicts response to concomitant radiochemotherapy in esophageal cancer</article-title>. <source>J Nucl Med</source>. <year>2011</year>; <volume>52</volume>(<issue>3</issue>):<fpage>369</fpage>&#x02013;<lpage>78</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2967/jnumed.110.082404">10.2967/jnumed.110.082404</ext-link></comment>
<pub-id pub-id-type="pmid">21321270</pub-id></mixed-citation></ref><ref id="pone.0161484.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Hamburg</surname><given-names>MA</given-names></name>, <name><surname>Collins</surname><given-names>FS</given-names></name>. <article-title>The path to personalized medicine</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>301</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMp1006304">10.1056/NEJMp1006304</ext-link></comment>
<pub-id pub-id-type="pmid">20551152</pub-id></mixed-citation></ref><ref id="pone.0161484.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Mankoff</surname><given-names>DA</given-names></name>, <name><surname>Pryma</surname><given-names>DA</given-names></name>, <name><surname>Clark</surname><given-names>AS</given-names></name>. <article-title>Molecular imaging biomarkers for oncology clinical trials</article-title>. <source>J Nucl Med</source>. <year>2014</year>;<volume>55</volume>:<fpage>1</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">24385310</pub-id></mixed-citation></ref><ref id="pone.0161484.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Zinn</surname><given-names>PO</given-names></name>, <name><surname>Mahmood</surname><given-names>Z</given-names></name>, <name><surname>Elbanan</surname><given-names>MG</given-names></name>, <name><surname>Colen</surname><given-names>RR</given-names></name>. <source>Imaging Genomics in Gliomas. Cancer J</source>. <year>2015</year>;<volume>21</volume>:<fpage>225</fpage>&#x02013;<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/PPO.0000000000000120">10.1097/PPO.0000000000000120</ext-link></comment>
<pub-id pub-id-type="pmid">26049703</pub-id></mixed-citation></ref><ref id="pone.0161484.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>DR</given-names></name>
<name><surname>O'Neill</surname><given-names>BP</given-names></name>. <article-title>Glioblastoma survival in the United States before and during the temozolomide era</article-title>. <source>J Neurooncol</source>. <year>2012</year>;<volume>107</volume>:<fpage>359</fpage>&#x02013;<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11060-011-0749-4">10.1007/s11060-011-0749-4</ext-link></comment>
<pub-id pub-id-type="pmid">22045118</pub-id></mixed-citation></ref><ref id="pone.0161484.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Hutterer</surname><given-names>M</given-names></name>, <name><surname>Hattingen</surname><given-names>E</given-names></name>, <name><surname>Palm</surname><given-names>C</given-names></name>, <name><surname>Proescholdt</surname><given-names>MA</given-names></name>, <name><surname>Hau</surname><given-names>P</given-names></name>. <article-title>Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients</article-title>. <source>Neur Oncol</source>. <year>2015</year>;<volume>17</volume>:<fpage>784</fpage>&#x02013;<lpage>800</lpage>.</mixed-citation></ref><ref id="pone.0161484.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Ellingson</surname><given-names>BM</given-names></name>. <article-title>Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics</article-title>. <source>Curr Neurol Neurosci Rep</source>. <year>2015</year>;<volume>15</volume>:<fpage>506</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11910-014-0506-0">10.1007/s11910-014-0506-0</ext-link></comment>
<pub-id pub-id-type="pmid">25410316</pub-id></mixed-citation></ref><ref id="pone.0161484.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Hygino da Cruz</surname><given-names>LC</given-names></name>, <name><surname>Rodriguez</surname><given-names>I</given-names></name>, <name><surname>Domingues</surname><given-names>RC</given-names></name>, <name><surname>Gasparetto</surname><given-names>EL</given-names></name>, <name><surname>Sorensen</surname><given-names>AG</given-names></name>. <article-title>Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma</article-title>. <source>Am J Neuro Radiol</source>. <year>2011</year>;<volume>32</volume>:<fpage>1978</fpage>&#x02013;<lpage>85</lpage>.</mixed-citation></ref><ref id="pone.0161484.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>O'Connor</surname><given-names>J</given-names></name>, <name><surname>Jackson</surname><given-names>A</given-names></name>, <name><surname>Asselin</surname><given-names>MC</given-names></name>, <name><surname>Buckley</surname><given-names>DL</given-names></name>, <name><surname>Parker</surname><given-names>GJ</given-names></name>, <name><surname>Jayson</surname><given-names>GC</given-names></name>. <article-title>Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives</article-title>. <source>Lancet Oncol</source>. <year>2008</year>;<volume>9</volume>:<fpage>766</fpage>&#x02013;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(08)70196-7">10.1016/S1470-2045(08)70196-7</ext-link></comment>
<pub-id pub-id-type="pmid">18672212</pub-id></mixed-citation></ref><ref id="pone.0161484.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>AR</given-names></name>, <name><surname>Weaver</surname><given-names>A</given-names></name>, <name><surname>Cummings</surname><given-names>PT</given-names></name>, <name><surname>Quaranta</surname><given-names>V</given-names></name>, <article-title>Tumor Morphology and Phenotypic Evolution Driven by Selective Pressure from the Microenvironment</article-title>, <source>Cell</source>
<year>2006</year>; <volume>127</volume>: <fpage>905</fpage>&#x02013;<lpage>915</lpage>. <pub-id pub-id-type="pmid">17129778</pub-id></mixed-citation></ref><ref id="pone.0161484.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>A</given-names></name>, <name><surname>Calvo</surname><given-names>GF</given-names></name>, <name><surname>P&#x000e9;rez Romasanta</surname><given-names>LA</given-names></name>, <name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>VM</given-names></name>. <article-title>Hypoxic Cell Waves Around Necrotic Cores in Glioblastoma: A Biomathematical Model and Its Therapeutic Implications</article-title>. <source>Bulletin of Mathematical Biology</source>. <year>2012</year>; <volume>74</volume>:<fpage>2875</fpage>&#x02013;<lpage>2896</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11538-012-9786-1">10.1007/s11538-012-9786-1</ext-link></comment>
<pub-id pub-id-type="pmid">23151957</pub-id></mixed-citation></ref><ref id="pone.0161484.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Pardo</surname><given-names>R</given-names></name>, <name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>A</given-names></name>, <name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>VM</given-names></name>. <article-title>Nonlinear ghost waves accelerate the progression of high-grade brain tumors</article-title>, <source>Commun Nonlin Sci Numer Simul</source>. <year>2016</year>; <volume>39</volume>: <fpage>360</fpage>&#x02013;<lpage>380</lpage>.</mixed-citation></ref><ref id="pone.0161484.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Verhaak</surname><given-names>RGW</given-names></name>, <name><surname>Hoadley</surname><given-names>KA</given-names></name>, <name><surname>Purdom</surname><given-names>E</given-names></name>, <name><surname>Wang</surname><given-names>V</given-names></name>, <name><surname>Qi</surname><given-names>Y</given-names></name>, <name><surname>Wilkerson</surname><given-names>MD</given-names></name>, <etal>et al</etal>
<article-title>An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1</article-title>. <source>Cancer Cell</source>. <year>2010</year>;<volume>17</volume>:<fpage>157</fpage>&#x02013;<lpage>73</lpage>.</mixed-citation></ref><ref id="pone.0161484.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Ellingson</surname><given-names>BJ</given-names></name>, <name><surname>Bendszus</surname><given-names>M</given-names></name>, <name><surname>Boxerman</surname><given-names>J</given-names></name>, <name><surname>Barboriak</surname><given-names>D</given-names></name>, <name><surname>Erickson</surname><given-names>BJ</given-names></name>, <name><surname>Smits</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Consensus recommendations for a standardized Brain Tumor Imaging Protocol in Clinical Trials</article-title>. <source>Neur Oncol</source>. <year>2015</year>;<volume>17</volume>:<fpage>1188</fpage>&#x02013;<lpage>98</lpage>.</mixed-citation></ref></ref-list></back></article>